NIH Trial Finds Tecovirimat Ineffective As Monotherapy For Mpox – SIGA Applied sciences (NASDAQ:SIGA)

SIGA Applied sciences’ SIGA antiviral drug tecovirimat, when used with out different therapies, didn’t cut back the time for clade II mpox lesions to heal or considerably alleviate ache, in line with outcomes from a world medical trial sponsored by the Nationwide Institutes of Well being (NIH).

The research, often called STOMP, was halted in late 2024 after an interim evaluation indicated the drug was ineffective within the research inhabitants.

Mpox has two identified variants: clades I and II. A clade II outbreak in 2022 led to international transmission, with continued low-level circulation.

In the meantime, a clade I outbreak in Central and East Africa was declared a public well being emergency in 2024.

STOMP launched in September 2022 as a part of a U.S. authorities initiative addressing the clade II mpox outbreak.

No mpox-specific therapies have been accepted within the U.S.

Tecovirimat, also called TPOXX, was initially approved by the FDA to deal with smallpox primarily based on animal research however had not been evaluated in people with mpox earlier than STOMP and a parallel research, PALM007, performed within the Democratic Republic of the Congo.

PALM007 yielded related outcomes from STOMP, additional questioning tecovirimat’s effectiveness for mpox.

Outcomes confirmed that by day 29, 83% of individuals taking tecovirimat had achieved medical decision, in comparison with 84% within the placebo group, indicating no significant distinction.

Amongst those that reported extreme ache on the research’s outset, ache discount was related throughout teams, with tecovirimat customers reporting a median lower of three.2 factors on an 11-point scale, in comparison with 3.1 factors for placebo recipients.

Viral DNA ranges declined over time in each teams, with no statistically important variations at key checkpoints.

Opposed occasion charges had been additionally comparable between therapy and placebo teams.

A separate exploratory evaluation examined STOMP’s open-label individuals—these at increased danger of extreme mpox. The evaluation discovered that youthful individuals and people with out HIV or with well-controlled HIV skilled quicker lesion decision.

Nonetheless, no robust correlation was noticed between symptom length earlier than research entry and restoration pace. Researchers famous that open-label individuals had fewer lesions however slower restoration in comparison with PALM007 trial individuals.

On Tuesday, SIGA Applied sciences reported fourth-quarter earnings of 63 cents, down from $1.01, and gross sales of $81.4 million, down $116.5 million from a 12 months in the past.

Value Motion: SIGA inventory is up 7.05% at $6.02 on the final test Wednesday.

Learn Subsequent:

Picture: Shutterstock